Effect of hyperthermic intraperitoneal chemotherapy for gastric cancer patients: a meta-analysis of the randomized controlled trials

Objective To determine the effectiveness and safety of hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced gastric cancer and peritoneal metastases. Methods PubMed®, CNKI, Web of Science, VIP and WANFANG databases were searched to identify randomized controlled trials (RCTs)...

Full description

Bibliographic Details
Main Authors: Yan-Wen Liu, Ying Du, Bao-An Chen
Format: Article
Language:English
Published: SAGE Publishing 2019-12-01
Series:Journal of International Medical Research
Online Access:https://doi.org/10.1177/0300060519882545
_version_ 1818838186196992000
author Yan-Wen Liu
Ying Du
Bao-An Chen
author_facet Yan-Wen Liu
Ying Du
Bao-An Chen
author_sort Yan-Wen Liu
collection DOAJ
description Objective To determine the effectiveness and safety of hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced gastric cancer and peritoneal metastases. Methods PubMed®, CNKI, Web of Science, VIP and WANFANG databases were searched to identify randomized controlled trials (RCTs) that examined the effect of HIPEC on survival, clinical response and adverse events. Patients with advanced gastric cancer and peritoneal metastases were divided into an experimental group and a control group. The statistical results are presented as relative ratio (RR), mean difference (MD) and 95% confidence interval (CI). Results Twenty-one RCTs met the inclusion criteria ( n  = 1674 patients). Meta-analysis showed that the 3-year survival rate was significantly higher in the HIPEC group than in the control group (RR 1.61; 95% CI 1.43, 1.82) and the complete response rate was significantly higher in the HIPEC group than in the control group (RR 2.35; 95% CI 1.67, 3.31). HIPEC was also beneficial in terms of decreased CEA (MD −1.79; 95% CI −2.22, −1.35). There was no significant difference in the rate of adverse reactions (RR 1.00; 95% CI 0.87, 1.14). Conclusions HIPEC had a beneficial effect on 3-year survival rate and complete response in patients with advanced gastric cancer and peritoneal metastases.
first_indexed 2024-12-19T03:34:23Z
format Article
id doaj.art-c99775cda1fc40ed9c5cb19b8618b44a
institution Directory Open Access Journal
issn 0300-0605
1473-2300
language English
last_indexed 2024-12-19T03:34:23Z
publishDate 2019-12-01
publisher SAGE Publishing
record_format Article
series Journal of International Medical Research
spelling doaj.art-c99775cda1fc40ed9c5cb19b8618b44a2022-12-21T20:37:25ZengSAGE PublishingJournal of International Medical Research0300-06051473-23002019-12-014710.1177/0300060519882545Effect of hyperthermic intraperitoneal chemotherapy for gastric cancer patients: a meta-analysis of the randomized controlled trialsYan-Wen LiuYing DuBao-An ChenObjective To determine the effectiveness and safety of hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced gastric cancer and peritoneal metastases. Methods PubMed®, CNKI, Web of Science, VIP and WANFANG databases were searched to identify randomized controlled trials (RCTs) that examined the effect of HIPEC on survival, clinical response and adverse events. Patients with advanced gastric cancer and peritoneal metastases were divided into an experimental group and a control group. The statistical results are presented as relative ratio (RR), mean difference (MD) and 95% confidence interval (CI). Results Twenty-one RCTs met the inclusion criteria ( n  = 1674 patients). Meta-analysis showed that the 3-year survival rate was significantly higher in the HIPEC group than in the control group (RR 1.61; 95% CI 1.43, 1.82) and the complete response rate was significantly higher in the HIPEC group than in the control group (RR 2.35; 95% CI 1.67, 3.31). HIPEC was also beneficial in terms of decreased CEA (MD −1.79; 95% CI −2.22, −1.35). There was no significant difference in the rate of adverse reactions (RR 1.00; 95% CI 0.87, 1.14). Conclusions HIPEC had a beneficial effect on 3-year survival rate and complete response in patients with advanced gastric cancer and peritoneal metastases.https://doi.org/10.1177/0300060519882545
spellingShingle Yan-Wen Liu
Ying Du
Bao-An Chen
Effect of hyperthermic intraperitoneal chemotherapy for gastric cancer patients: a meta-analysis of the randomized controlled trials
Journal of International Medical Research
title Effect of hyperthermic intraperitoneal chemotherapy for gastric cancer patients: a meta-analysis of the randomized controlled trials
title_full Effect of hyperthermic intraperitoneal chemotherapy for gastric cancer patients: a meta-analysis of the randomized controlled trials
title_fullStr Effect of hyperthermic intraperitoneal chemotherapy for gastric cancer patients: a meta-analysis of the randomized controlled trials
title_full_unstemmed Effect of hyperthermic intraperitoneal chemotherapy for gastric cancer patients: a meta-analysis of the randomized controlled trials
title_short Effect of hyperthermic intraperitoneal chemotherapy for gastric cancer patients: a meta-analysis of the randomized controlled trials
title_sort effect of hyperthermic intraperitoneal chemotherapy for gastric cancer patients a meta analysis of the randomized controlled trials
url https://doi.org/10.1177/0300060519882545
work_keys_str_mv AT yanwenliu effectofhyperthermicintraperitonealchemotherapyforgastriccancerpatientsametaanalysisoftherandomizedcontrolledtrials
AT yingdu effectofhyperthermicintraperitonealchemotherapyforgastriccancerpatientsametaanalysisoftherandomizedcontrolledtrials
AT baoanchen effectofhyperthermicintraperitonealchemotherapyforgastriccancerpatientsametaanalysisoftherandomizedcontrolledtrials